ASRS
BMRN icon

Arizona State Retirement System’s BioMarin Pharmaceuticals BMRN Stock Holding History

Arizona State Retirement System’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.81M Sell
49,088
-1,043
-2% -$57.1K 0.01% 664
2026
Q1 		$2.83M Buy
50,131
+32
+0.1% +$1.87K 0.02% 618
2025
Q4 		$2.98M Sell
50,099
-6,635
-12% -$361K 0.02% 616
2025
Q3 		$3.07M Buy
56,734
+716
+1% +$40.9K 0.02% 613
2025
Q2 		$3.08M Buy
56,018
+943
+2% +$55.5K 0.02% 593
2025
Q1 		$3.89M Sell
55,075
-205
-0.4% -$13.8K 0.02% 489
2024
Q4 		$3.63M Buy
55,280
+880
+2% +$58.9K 0.02% 524
2024
Q3 		$3.82M Buy
54,400
+2,270
+4% +$190K 0.02% 518
2024
Q2 		$4.29M Buy
52,130
+320
+0.6% +$26.6K 0.03% 441
2024
Q1 		$4.53M Buy
51,810
+92
+0.2% +$8.24K 0.03% 438
2023
Q4 		$4.99M Buy
51,718
+510
+1% +$45.1K 0.04% 389
2023
Q3 		$4.53M Buy
51,208
+10
+0% +$890 0.04% 383
2023
Q2 		$4.44M Sell
51,198
-2,833
-5% -$267K 0.04% 404
2023
Q1 		$5.25M Buy
54,031
+1,532
+3% +$159K 0.05% 365
2022
Q4 		$5.43M Buy
52,499
+1,705
+3% +$160K 0.05% 347
2022
Q3 		$4.31M Sell
50,794
-568
-1% -$50.6K 0.04% 377
2022
Q2 		$4.26M Buy
51,362
+257
+0.5% +$20.5K 0.04% 393
2022
Q1 		$3.94M Buy
51,105
+1,184
+2% +$99.1K 0.03% 485
2021
Q4 		$4.41M Sell
49,921
-1,363
-3% -$112K 0.03% 461
2021
Q3 		$3.96M Sell
51,284
-85
-0.2% -$6.71K 0.03% 482
2021
Q2 		$4.29M Sell
51,369
-970
-2% -$76.9K 0.03% 464
2021
Q1 		$3.95M Buy
52,339
+337
+0.6% +$27.5K 0.03% 477
2020
Q4 		$4.56M Sell
52,002
-3,024
-5% -$240K 0.04% 396
2020
Q3 		$4.19M Buy
55,026
+13,135
+31% +$1.33M 0.04% 380
2020
Q2 		$5.17M Buy
41,891
+554
+1% +$55.1K 0.07% 253
2020
Q1 		$3.49M Buy
+41,337
New +$3.56M 0.06% 360
2018
Q2 		– Sell
-30,034
Closed -$2.44M – 1531
2018
Q1 		$2.44M Sell
30,034
-3,200
-10% -$275K 0.02% 886
2017
Q4 		$2.96M Buy
33,234
+2,328
+8% +$202K 0.03% 816
2017
Q3 		$2.88M Buy
+30,906
New +$2.73M 0.03% 585

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Arizona State Retirement System's BMRN Position: Q2 2026 in Review

Arizona State Retirement System reduced its BioMarin Pharmaceuticals (BMRN) stake by 2.1% in Q2 2026, selling an estimated $57.1K and leaving 49,088 shares worth $2.81M. The position accounts for 0.01% of the portfolio, ranked #664.

Arizona State Retirement System first reported a position in BMRN in Q3 2017 and has held it in 29 quarters since. The position peaked at $5.43M in Q4 2022. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Arizona State Retirement System held 49,088 shares of BioMarin Pharmaceuticals worth $2.81M as of Q2 2026.
  • Arizona State Retirement System sold 1,043 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $57.1K.
  • BioMarin Pharmaceuticals made up 0.01% of Arizona State Retirement System's portfolio in Q2 2026, its #664 holding.
  • Arizona State Retirement System first reported a position in BioMarin Pharmaceuticals in Q3 2017 and has held it in 29 quarters since.
  • Arizona State Retirement System's BioMarin Pharmaceuticals position peaked at $5.43M in Q4 2022.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Arizona State Retirement System's 13F filing for Q2 2026, filed 7 Aug 2026.